These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 17151003

  • 1. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
    Liu R, Abid K, Pichardo J, Pazienza V, Ingravallo P, Kong R, Agrawal S, Bogen S, Saksena A, Cheng KC, Prongay A, Njoroge FG, Baroudy BM, Negro F.
    J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
    Horscroft N, Bellows D, Ansari I, Lai VC, Dempsey S, Liang D, Donis R, Zhong W, Hong Z.
    J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
    [Abstract] [Full Text] [Related]

  • 4. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K, Kwong AD, Lin C.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M, Bailey MD, Ghiro E, Gorys V, Halmos T, Poirier M, Rancourt J, Goudreau N.
    J Med Chem; 2004 Dec 16; 47(26):6584-94. PubMed ID: 15588093
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS.
    Biopolymers; 2004 Dec 16; 76(4):309-23. PubMed ID: 15386268
    [Abstract] [Full Text] [Related]

  • 12. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
    Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H.
    Antiviral Res; 2009 Feb 16; 81(2):166-73. PubMed ID: 19063924
    [Abstract] [Full Text] [Related]

  • 13. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
    Bogen SL, Ruan S, Liu R, Agrawal S, Pichardo J, Prongay A, Baroudy B, Saksena AK, Girijavallabhan V, Njoroge FG.
    Bioorg Med Chem Lett; 2006 Mar 15; 16(6):1621-7. PubMed ID: 16387495
    [Abstract] [Full Text] [Related]

  • 14. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2295-8. PubMed ID: 19285390
    [Abstract] [Full Text] [Related]

  • 15. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M.
    Nature; 2003 Nov 13; 426(6963):186-9. PubMed ID: 14578911
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
    Hahm B, Back SH, Lee TG, Wimmer E, Jang SK.
    Virology; 1996 Dec 15; 226(2):318-26. PubMed ID: 8955051
    [Abstract] [Full Text] [Related]

  • 18. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P, Jean F.
    Biochemistry; 2005 May 03; 44(17):6586-96. PubMed ID: 15850392
    [Abstract] [Full Text] [Related]

  • 19. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G, Sandström A, Akerblom E, Danielson UH.
    Antivir Ther; 2007 May 03; 12(5):733-40. PubMed ID: 17713156
    [Abstract] [Full Text] [Related]

  • 20. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
    Bourne N, Pyles RB, Yi M, Veselenak RL, Davis MM, Lemon SM.
    Antiviral Res; 2005 Aug 03; 67(2):76-82. PubMed ID: 15927278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.